Bevacizumab plus paclitaxel versus placebo plus paclitaxel as first-line therapy for HER2-negative metastatic breast cancer (MERiDiAN): A double-blind placebo-controlled randomised phase III trial with prospective biomarker evaluation
European Journal of Cancer2016Vol. 70, pp. 146–155
Citations Over TimeTop 10% of 2016 papers
David Miles, David Cameron, Igor Bondarenko, Lyudmila Manzyuk, Juan Carlos Alcedo, R.I. Lopez, Seock‐Ah Im, Jean‐Luc Canon, Yaroslav Shparyk, Denise A. Yardley, Norikazu Masuda, Jungsil Ro, Neelima Denduluri, Stanislas Hubeaux, Cheng S. Quah, Carlos Bais, Joyce O’Shaughnessy
Related Papers
- → Bevacizumab in metastatic breast cancer: a meta-analysis of randomized controlled trials(2010)90 cited
- → The efficacy of bevacizumab plus paclitaxel as first-line treatment for HER2-negative metastatic breast cancer: a meta-analysis of randomized controlled trials(2014)7 cited
- → Bevacizumab in the first-line treatment of metastatic breast cancer(2008)13 cited
- → The efficacy and its related issues of combination of bevacizumab and taxanes-based regimens in Chinese patients with metastatic breast cancer(2012)2 cited
- → Docetaxel and bevacizumab with or without trastuzumab as first-line treatment for patients with metastatic breast cancer: a meta-analysis.(2021)